Who
Philip W. Kantoff
Director
Company insider
Files Form 4 as: Director, Context Therapeutics; Director, ESSA Pharma.
In numbers
- Trades disclosed
- 7
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Jun 2022
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,500 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 Mar 2024filed 28 Mar 2024 | ESSA Pharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 31 May 2023filed 31 May 2023 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.